Shikonin inhibits the growth of human prostate cancer cells via modulation of the androgen receptor

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1455-1460

  Jang, Soon Young ^a   Jang, Eun Hyang ^a   Jeong, Seo YOUNG ^a   Kim, Jong H O ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Androgen receptor; Anticancer; Prostate cancer; Shikonin

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; SHIKONIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; LNCAP CELL LINE; LUCIFERASE ASSAY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSCRIPTION TERMINATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NAPHTHOQUINONES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84899084399     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2306     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005. (Pubitemid 40310185)
2. Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015, 2002.
3. Culig Z, Klocker H, Bartsch G and Hobisch A: Androgen receptors in prostate cancer. Endocr Relat Cancer 9: 155-170, 2002. (Pubitemid 35175976)
4. Prescott J and Coetzee GA: Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 231: 12-19, 2006. (Pubitemid 41779448)
5. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004. (Pubitemid 38501396)
6. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39, 2004. (Pubitemid 38524696)
7. Isaacs JT and Isaacs WB: Androgen receptor outwits prostate cancer drugs. Nat Med 10: 26-27, 2004. (Pubitemid 38524693)
8. Masuda Y, Nishida A, Hori K, et al: Beta-hydroxyisovaleryl-shikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). Oncogene 22: 1012-1023, 2003.
9. Kim SH, Kang IC, Yoon TJ, et al: Antitumor activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S-33. Cancer Lett 172: 171-175, 2001. (Pubitemid 32889713)
10. Masuda Y, Shima G, Aiuchi T, et al: Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J Biol Chem 279: 42503-42515, 2004. (Pubitemid 39372134)
11. Yoon Y, Kim YO, Lim NY, Jeon WK and Sung HJ: Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med 65: 532-535, 1999. (Pubitemid 29399955)
12. Yang H, Zhou P, Huang H, et al: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 124: 2450-2459, 2009.
13. Gaddipati JP, Mani H, Shefali, et al: Inhibition of growth and regulation of IGFs and VEGF in human prostate cancer cell lines by shikonin analogue 93/637 (SA). Anticancer Res 20: 2547-2552, 2000.
14. Wu Z, Wu L, Li L, Tashiro S, Onodera S and Ikejima T: p53?mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci 94: 166-176, 2004. (Pubitemid 38405131)
15. Chung TW, Moon SK, Chang YC, et al: Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. FASEB J 18: 1670-1681, 2004.
16. Balk SP, Ko YJ and Bubley GJ: Biology of prostate-specific antigen. J Clin Oncol 21: 383-391, 2003. (Pubitemid 46606169)
17. Burnstein KL: Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem 95: 657-669, 2005.
18. Rosenfeld MG and Glass CK: Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276: 36865-36868, 2001.
19. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
20. Nelson WG, De Marzo AM and Isaacs WB: Prostate cancer. N Engl J Med 349: 366-381, 2003. (Pubitemid 36886244)
21. Richter E, Srivastava S and Dobi A: Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 10: 114-118, 2007. (Pubitemid 46881662)
22. Tamura K, Furihata M, Tsunoda T, et al: Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 67: 5117-5125, 2007. (Pubitemid 46997247)
23. Sankawa U, Ebizuka Y, Miyazaki T, Isomura Y and Otsuka H: Antitumor activity of shikonin and its derivatives. Chem Pharm Bull 25: 2392-2395, 1977. (Pubitemid 8196664)
24. Han W, Li L, Qiu S, et al: Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 6: 1641-1649, 2007. (Pubitemid 46954031)
25. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V and Della Ragione F: Resveratrol: from basic science to the clinic. Cell Cycle 6: 2495-2510, 2007. (Pubitemid 350058668)